The Heavy Price of GLP-1 Drugs – I-MAK
US$ 28.68
semaglutide novo nordisk patent expiry opens door to cheaper weight-loss drugs in India Patent expires next year: Novo
Description
Fortunately, this is easily avoided
Heart rate Resting heart rate rose by about 1-4 beats per minute in clinical trials
It does not diagnose MASH, measure fibrosis, or predict whether semaglutide is suitable
Currently, there is a lack of data regarding the cost-effectiveness and long-term diabetes-related outcomes of oral semaglutide compared to other subcutaneous GLP-1 RAs
Transparent Operations at 69/100 reflects hidden pricing, a two-month commitment buried in fine print, unexplained media logos, and poor medication format explanations
& Raffone, E
